IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST OF THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT

This announcement is made by IMPACT Therapeutics, Inc (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the Company's shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that the H shares of the Company (the "**H Shares**") are included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs (the "**Stock Connect Programs**") with effect from September 7, 2026, pursuant to the announcements made by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, respectively.

The inclusion of the H Shares in the list of eligible securities under the Stock Connect Programs allows eligible investors in the Chinese Mainland to directly invest in the H Shares via the Shanghai Stock Exchange and the Shenzhen Stock Exchange. The Company believes that the inclusion in the Stock Connect Programs will further expand the Company's investor base and potentially enhance the trading liquidity of the Company's H Shares.

Information on the Stock Connect Programs

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are stock market trading mechanisms which allow interconnectivity and mutual access. The Shanghai Stock Exchange, the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited have established technical connectivity to enable investors in the Chinese Mainland and the Hong Kong Special Administrative Region of the People's Republic of China to trade eligible stocks listed on each other's stock exchange through their local securities firms or brokers.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, September 7, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.